These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 2149268)

  • 21. Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process.
    Anglés-Cano E
    Braz J Med Biol Res; 1997 Nov; 30(11):1271-80. PubMed ID: 9532233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Modified lipoproteins in atherosclerotic lesions of human aorta].
    Wang X; Chen Q; Zhu Q
    Zhonghua Bing Li Xue Za Zhi; 1998 Feb; 27(1):6-9. PubMed ID: 11244945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator.
    Liu JN; Harpel PC; Pannell R; Gurewich V
    Biochemistry; 1993 Sep; 32(37):9694-700. PubMed ID: 8373773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein(a), plasmin modulation, and atherogenesis.
    Harpel PC; Hermann A; Zhang X; Ostfeld I; Borth W
    Thromb Haemost; 1995 Jul; 74(1):382-6. PubMed ID: 8578490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta.
    Bihari-Varga M; Gruber E; Rotheneder M; Zechner R; Kostner GM
    Arteriosclerosis; 1988; 8(6):851-7. PubMed ID: 2973783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques.
    Reblin T; Meyer N; Labeur C; Henne-Bruns D; Beisiegel U
    Atherosclerosis; 1995 Mar; 113(2):179-88. PubMed ID: 7605357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteolytic degradation of low-density lipoprotein by lipoprotein(a) and by recombinant apo(a).
    Pursiainen M; Jauhiainen M; Kovanen PT; Ehnholm C
    Chem Phys Lipids; 1994 Jan; 67-68():25-33. PubMed ID: 8187221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro inhibition of fibrinolysis by apolipoprotein(a) and lipoprotein(a) is size- and concentration-dependent.
    Knapp JP; Herrmann W
    Clin Chem Lab Med; 2004; 42(9):1013-9. PubMed ID: 15497466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hedgehog lipoprotein(a) is a modulator of activation of plasminogen at the fibrin surface. An in vitro study.
    Rouy D; Laplaud PM; Saboureau M; Anglés-Cano E
    Arterioscler Thromb; 1992 Feb; 12(2):146-54. PubMed ID: 1531929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima.
    Nielsen LB; Grønholdt ML; Schroeder TV; Stender S; Nordestgaard BG
    Arterioscler Thromb Vasc Biol; 1997 May; 17(5):905-11. PubMed ID: 9157954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin.
    Liu J; Harpel PC; Gurewich V
    Biochemistry; 1994 Mar; 33(9):2554-60. PubMed ID: 8117716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partial characterization of lipoproteins containing apo[a] in human atherosclerotic lesions.
    Hoff HF; O'Neil J; Yashiro A
    J Lipid Res; 1993 May; 34(5):789-98. PubMed ID: 8509717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic basis and pathophysiological implications of high plasma Lp(a) levels.
    Scanu AM
    J Intern Med; 1992 Jun; 231(6):679-83. PubMed ID: 1535652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein.
    Simon DI; Fless GM; Scanu AM; Loscalzo J
    Biochemistry; 1991 Jul; 30(27):6671-7. PubMed ID: 1829635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of free and tightly bound lipoprotein in intima by thin layer isoelectric focusing.
    Smith EB; Dietz HS; Craig IB
    Atherosclerosis; 1979 Jul; 33(3):329-42. PubMed ID: 226107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments.
    Rouy D; Koschinsky ML; Fleury V; Chapman J; Anglés-Cano E
    Biochemistry; 1992 Jul; 31(27):6333-9. PubMed ID: 1627572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of fibrinolysis by lipoprotein(a).
    Anglés-Cano E; de la Peña Díaz A; Loyau S
    Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein(a) and atherosclerosis.
    Scanu AM; Lawn RM; Berg K
    Ann Intern Med; 1991 Aug; 115(3):209-18. PubMed ID: 1829339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects.
    Knight BL; Perombelon YF; Soutar AK; Wade DP; Seed M
    Atherosclerosis; 1991 Apr; 87(2-3):227-37. PubMed ID: 1830206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux.
    Nielsen LB
    Atherosclerosis; 1999 Apr; 143(2):229-43. PubMed ID: 10217351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.